NICE recommends CAMZYOS as an option for treating symptomatic obstructive HCM in adults who have a NYHA class of II to III only if: it is used as an add-on to individually optimised standard of care that includes beta blockers, non-dihydropyridine calcium channel blockers or disopyramide, unless these are contraindicated; and BMS provides CAMZYOS according to the commercial agreement.1
CAMZYOS (mavacamten) is recommended by NICE for the treatment of symptomatic obstructive HCM1